Engineered antigen presenting cells and methods for their use
US5962320A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jul 3, 1997 |
| Grant date | Oct 5, 1999 |
| Priority date | — |
| Expiry date | Jul 3, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/12043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Autologous, heterologous or xenogeneic primary cells or cell lines are genetically modified ex vivo to render the cells capable of processing and presenting selected antigens to cells of the immune system of a subject, and to express different HLA molecules for matching to the HLA specificity of the subject. The cells are also modified to express immunoregulatory molecules for directing the immune response of the subject. The cells and cell lines are used in methods to treat infectious diseases or cancer, or to prevent infectious disease by inoculation into a host to activate T cells and induce an antigen-specific immune response, and in assays of the cytolytic activity of a subject's T cells. The cells can also be used to suppress an unwanted immune response of a subject to a selected antigen where the cells lack expression of a costimulation molecule needed for T cell activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.